Thermo Fisher Scientific VEGF Monoclonal Antibody (A183C 13G8)

Applications and Publications

Immunohistochemistry (IHC)

• Tested Dilution: -
• View 1 publication

ELISA

• Tested Dilution: Assay-dependent
• View 1 publication

Miscellaneous (PubMed)

• Tested Dilution: -
• View 1 publication

Product Specifications

Product Specific Information

This product is recommended as a capture antibody in Sandwich ELISA applications.

Target Information

VEGF (vascular endothelial growth factor) is a 45 kDa homodimeric, disulfide-linked glycoprotein involved in angiogenesis that promotes tumor progression and metastasis. VEGF affects vascular endothelium by promoting endothelial cell viability, mitogenesis, chemotaxis, and vascular permeability.
The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptors are key regulators in angiogenesis signaling. Most tumors depend on angiogenesis, and VEGF is the most potent angiogenic cytokine in this process.
Five VEGF isoforms are generated by alternative splicing from a single gene, binding mainly to tyrosine-kinase receptors FLT1 (VEGFR-1) and FLK1/KDR (VEGFR-2), primarily expressed on endothelial cells.
A soluble form of FLT1 (sFLT1) binds VEGF with high affinity and inhibits angiogenesis. Elevated VEGF levels are associated with POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, Skin changes), also known as Crow-Fukase syndrome.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.